Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Revive Therapeutics Ltd. (C:RVV)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 82 Richmond Street East
TORONTO ON M5C 1P1
Tel: N/A
Website: https://revivethera.com
IR: See website
Key People
Michael Frank
Executive Chairman of the Board, Chief Executive Officer
Carmelo Marrelli
Chief Financial Officer, Corporate Secretary
 
Business Overview
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Financial Overview
For the six months ended 31 December 2023, Revive Therapeutics Ltd revenues was not reported. Net loss decreased 64% to C$1.2M. Lower net loss reflects Research costs decrease of 76% to C$567K (expense), Administrative decrease from C$187K (expense) to C$47K (income), Office expenses decrease of 67% to C$48K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $8.58M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$3.65M as of Dec 31, 2023
Net annual income (TTM): -$4.30M as of Dec 31, 2023
Free cash flow (TTM): -$4.10M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 418,564,269 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization